NYSE : BMY
Bristol-Myers Squibb Company — Key statistics
Healthcare · Drug Manufacturers - General · United States
Last price 62.48 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 127.71B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 127.71B |
| Enterprise Value | 159.57B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | Oct 2, 2026 |
Shares
| Measure | Value |
|---|
| Current Share Class | 2.04B |
| Shares Outstanding | 2.04B |
| Shares Change (YoY) | +0.48% |
| Shares Change (QoQ) | +0.24% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 82.93% |
| Float | 2.04B |
Ratios
| Measure | Value |
|---|
| PE Ratio | 13.84 |
| Forward PE | 9.72 |
| PS Ratio | 2.55 |
| Forward PS | 2.62 |
| PB Ratio | 5.46 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 13.75 |
| P/OCF Ratio | 11.99 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 17.26 |
| EV / Sales | 3.19 |
| EV / EBITDA | 8.75 |
| EV / EBIT | 9.85 |
| EV / FCF | 17.18 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.59 |
| Quick Ratio | 1.36 |
| Debt / Equity | 1.91 |
| Debt / EBITDA | 2.41 |
| Debt / FCF | 4.83 |
| Interest Coverage | 9.87 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 44.01% |
| Return on Assets (ROA) | 10.90% |
| Return on Invested Capital (ROIC) | 23.60% |
| Return on Capital Employed (ROCE) | 23.13% |
| Weighted Average Cost of Capital (WACC) | 4.67% |
| Revenue Per Employee | $1.54M |
| Profits Per Employee | $284,400 |
| Employee Count | 32,500 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 5.40 |
Taxes
| Measure | Value |
|---|
| Income Tax | 2.09B |
| Effective Tax Rate | 18.44% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.18 |
| 52-Week Price Change | +46.67% |
| 50-Day Moving Average | 62.80 |
| 200-Day Moving Average | 59.95 |
| Relative Strength Index (RSI) | 54.71 |
| Average Volume (20 Days) | 12,448,485 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 49.95M |
| Short Previous Month | 41.97M |
| Short % of Shares Out | 2.44% |
| Short % of Float | 2.45% |
| Short Ratio (days to cover) | 3.50 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 50.03B |
| Gross Profit | 35.28B |
| Operating Income | 16.19B |
| Pretax Income | 11.33B |
| Net Income | 9.24B |
| EBITDA | 18.24B |
| EBIT | 16.19B |
| Earnings Per Share (EPS) | $4.51 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 12.58B |
| Total Debt | 44.81B |
| Net Cash | -31.85B |
| Net Cash Per Share | -$15.58 |
| Equity (Book Value) | 23.40B |
| Book Value Per Share | 11.45 |
| Working Capital | 11.01B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 10.65B |
| Capital Expenditures | -1.37B |
| Depreciation & Amortization | 2.05B |
| Net Borrowing | -6.26B |
| Free Cash Flow | 9.29B |
| FCF Per Share | $4.54 |
Margins
| Measure | Value |
|---|
| Gross Margin | 70.50% |
| Operating Margin | 32.36% |
| Pretax Margin | 22.65% |
| Profit Margin | 18.47% |
| EBITDA Margin | 36.46% |
| EBIT Margin | 32.36% |
| FCF Margin | 18.56% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | $2.52 |
| Dividend Yield | 4.03% |
| Dividend Growth (YoY) | 1.61% |
| Years of Dividend Growth | 19 |
| Payout Ratio | 55.84% |
| FCF Payout Ratio | 55.47% |
| Buyback Yield | -0.48% |
| Shareholder Yield | 3.55% |
| Earnings Yield | 7.22% |
| FCF Yield | 7.27% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $65.25 |
| Price Target Difference | 4.43% |
| Analyst Consensus | Hold |
| Analyst Count | 28 |
| Revenue Growth Forecast (3Y) | -5.65% |
| EPS Growth Forecast (3Y) | -4.77% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Mar 1, 1999 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 2.71 |
| Piotroski F-Score | 7 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |